• Non ci sono risultati.

Trattamento di I Linea

N/A
N/A
Protected

Academic year: 2022

Condividi "Trattamento di I Linea"

Copied!
88
0
0

Testo completo

(1)

I tumori del rene:

Trattamento di I linea

Novità diagnostico terapeutiche nel carcinoma renale e prostatico Campobasso, 19 Settembre 2019

Enrico Ricevuto & Gemma Bruera Assistenza Oncologica Territoriale Ospedale S. Salvatore L’Aquila Rete Oncologica ASL1 Abruzzo

Dipartimento Scienze Cliniche Applicate e Biotecnologiche

Università dell’Aquila

(2)

2

2

mRCC: I Line Treatment Options

Medical Treatments

VEGFR-TKI: Sunitinib, Pazopanib, Tivozanib

Immunotherapy: Nivolumab/Ipilimumab

MET-Inhibitors: Cabozantinib

Cytoreductive nephrectomy, Metastasectomy and post-operative treatment

Active surveillance

Medical Treatments: Perspectives

VEGFR-TKI/Immunotherapy Associations:

Pembrolizumab/Axitinib

Atezolizumab/Bevacizumab

Avelumab/Sunitinib

(3)

3

A retrospective study utilizing 2000–2010 SEER data evaluated changes in survival between pre-targeted therapy and targeted therapy periods in advanced RCC

Patients in the targeted therapy era showed improved survival compared with those diagnosed in the pretarget therapy era (HR, 0.86, P<0.01)

Overall Survival in the Pre-targeted Therapy vs Targeted Therapy Eras

HR, hazard ratio; RCC, renal cell carcinoma; SEER, Surveillance, Epidemiology, and End Results.

Li P et al. Cancer Med 2016;5:169–81.

Pretarget Era (2000–2005): N=7,231 Targeted Era (2006–2010): N=6,439

Years 0

0.25 0.50 0.75 1.00

1 2 3 4 5 6

Overall Survival, Advanced RCC

Overall Survival (Probability)

(4)

4

(5)

5

(6)

6

(7)

7

(8)

8

(9)

9

Lee et al, Ann Onc 2015

Bracarda et al, Ann Onc 2016

(10)

10

(11)

11

mRCC: I Line treatment

IMDC risk Prognostic Score

(12)

12

(13)

13

(14)

14

mRCC: I Line treatment

Checkmate 214

(15)

15

mRCC: I Line treatment

Checkmate 214, Baseline Characteristics

(16)

17

mRCC I Line treatment

Checkmate 214: IMDC Intermediate/Poor, OR/DOR

(17)

18

mRCC I Line treatment

Checkmate 214: IMDC Intermediate/Poor, PFS/IRRC

(18)

19

mRCC I Line treatment

Checkmate 214: IMDC Intermediate/Poor, OS

(19)

20

(20)

21

mRCC I Line treatment

Checkmate 214: ITT, ORR/PFS/OS

(21)

22

mRCC I Line treatment

Checkmate 214: Activity by PDL1 expression

(22)

23

mRCC I Line treatment

Checkmate 214: IMDC Intermediate/Poor, PFS by PDL1

(23)

24

mRCC I Line treatment

Checkmate 214: Responders, OS/TTR/TTP/Duration of therapy

(24)

25

mRCC I Line treatment

Checkmate 214: Sarcomatoid, Intermediate/Poor, OR

(25)

26

mRCC I Line treatment

Checkmate 214: Sarcomatoid, IMDC Intermediate/Poor, PFS IA

(26)

27

mRCC I Line treatment

Checkmate 214: Sarcomatoid, IMDC Intermediate/Poor, OS

(27)

28

(28)

29

mRCC I Line treatment

Checkmate 214

(29)

30

mRCC I Line treatment

Checkmate 214

(30)

31

mRCC I Line treatment

Checkmate 214

(31)

32

mRCC I Line treatment

Checkmate 214

(32)

33

mRCC I Line treatment

Checkmate 214

(33)

34

mRCC I Line treatment

Checkmate 214

(34)

35

mRCC I Line treatment

Checkmate 214

(35)

36

mRCC I Line treatment

Checkmate 214

(36)
(37)
(38)
(39)
(40)
(41)
(42)
(43)

44

cc mRCC: I Line treatment

Options

(44)

Slide 21

Presented By Robert Uzzo at 2019 ASCO Annual Meeting

(45)

CARMENA: Prospective, multicenter, open-label, randomized, phase 3 non-inferiority study

Presented By Arnaud Mejean at 2019 ASCO Annual Meeting

(46)

Slide 11

Presented By Arnaud Mejean at 2019 ASCO Annual Meeting

(47)

Patient characteristics (2) / classification by IMDC

Presented By Arnaud Mejean at 2019 ASCO Annual Meeting

(48)

Median Overall Survival (ITT), FU = 61.5 months

Presented By Arnaud Mejean at 2019 ASCO Annual Meeting

(49)

Slide 20

Presented By Arnaud Mejean at 2019 ASCO Annual Meeting

(50)

Median Overall Survival (ITT) Intermediate patients

Presented By Arnaud Mejean at 2019 ASCO Annual Meeting

(51)

Median OS (ITT) patients with 1 metastatic site vs >1

Presented By Arnaud Mejean at 2019 ASCO Annual Meeting

(52)

Secondary nephrectomy in Arm B (sunitinib alone)

Presented By Arnaud Mejean at 2019 ASCO Annual Meeting

(53)

Slide 32

Presented By Arnaud Mejean at 2019 ASCO Annual Meeting

(54)
(55)

58

(56)

Slide 14

Presented By Neeraj Agarwal at 2019 ASCO Annual Meeting

(57)

60

(58)

Slide 15

Presented By Neeraj Agarwal at 2019 ASCO Annual Meeting

(59)

62

(60)

63

(61)

64

64

mRCC: I Line Treatment Options

Medical Treatments

VEGFR-TKI: Sunitinib, Pazopanib, Tivozanib

Immunotherapy: Nivolumab/Ipilimumab

MET-Inhibitors: Cabozantinib

Cytoreductive nephrectomy, Metastasectomy and post-operative treatment

Active surveillance

Medical Treatments: Perspectives

VEGFR-TKI/Immunotherapy Associations:

Pembrolizumab/Axitinib

Atezolizumab/Bevacizumab

Avelumab/Sunitinib

(62)

Efficacy of therapy is improving…

Presented By Bradley McGregor at 2019 ASCO Annual Meeting

mRCC: I Line treatment

Conclusions

(63)
(64)

861

(FASE3)

 KPS < 80% -Interval from diagnosis to metastatic disease < 12months -Corrected serum calcium >10 mg/dl - Platelets > ULN - Neutrophils > ULN - Low Hb

(65)
(66)

KEYNOTE-426: OS in the ITT Population

Presented By Brian Rini at 2019 ASCO Annual Meeting

(67)
(68)
(69)

IMDC Favorable Risk: OS, PFS, and ORR

Presented By Brian Rini at 2019 ASCO Annual Meeting

(70)

IMDC Intermediate/Poor Risk: OS, PFS, and ORR

Presented By Brian Rini at 2019 ASCO Annual Meeting

(71)

PFS: Presence of Sarcomatoid Featuresa

Presented By Brian Rini at 2019 ASCO Annual Meeting

(72)

IMmotion151 Study Design

Key eligibility

• Treatment-naive advanced or metastatic RCC

• Clear cell and/or sarcomatoid histology

• KPS ≥ 70

• Tumor tissue available for PD-L1 staining

R 1:1

Atezolizumab 1200 mg IV q3w +

Bevacizumab 15 mg/kg IV q3w

Sunitinib 50 mg PO QD (4 weeks on, 2 weeks off)

N = 915

Stratification

•MSKCC risk score

•Liver metastases

•PD-L1 IC IHC status (< 1% vs ≥ 1%)a

Co-primary endpoints

• PFS by INV assessment in PD-L1+

• OS in ITT

Other key endpoints

• PFS in ITT

• OS in PD-L1+

• ORR

• Patient-reported outcomes

• Safety

IC, tumor-infiltrating immune cell; IHC, immunohistochemistry; INV, investigator; IRC, independent review committee; ITT, intent-to-treat; IV, intravenous; ORR, overall response rate; OS, overall survival; PD-L1, programmed death-ligand 1; PFS, progression-free survival; PO, by mouth; R, randomized; RCC, renal cell carcinoma; KPS, Karnofsky Performance Status; MKSCC, Memorial Sloan

Kettering Cancer Center; q3w, every 3 weeks; QD, once a day.

a 40% prevalence using SP142 IHC assay.

Motzer RJ, et al. ASCO GU 2018 [abstract 578].

(73)

Progression-Free Survival in the PD-L1+

Population

Median PFS, mo (95% CI) Atezo + Bev 11.2 (8.9, 15.0) Sunitinib 7.7 (6.8, 9.7)

HR, 0.74 (95% CI: 0.57, 0.96) P = 0.02a

PFS assessed by investigators. Minimum follow- up, 12 months. Median follow-up, 16 months.

a The PFS analysis passed the pre-specified P value boundary of α = 0.04.

Motzer RJ, et al. ASCO GU 2018 [abstract 578].

(74)

Efficacy Summary

PD-L1+ ITT

Atezo + Bev n = 178

Sunitinib n = 184

Atezo + Bev n = 454

Sunitinib n = 461a

Median PFS, mo (95% CI)

Stratified HR, (95% CI)

11.2 (8.9, 15.0) 7.7 (6.8, 9.7) 11.2 (9.6, 13.3) 8.4 (7.5, 9.7)

0.74 (0.57, 0.96) 0.83 (0.70, 0.97)

Overall survival, mo

Interim analysisb

Stratified HR, (95% CI)

Not reached 23.3 (21.3, NR) Not reached Not reached

0.68 (0.46, 1.00) 0.81 (0.63, 1.03)

c

Confirmed ORR, % (95% CI)

Complete response

43% (35, 50)

9%

35% (28, 42)

4%

37% (32, 41)

5%

33% (29, 38)

2%

a n = 460 for ORR analysis.

b Event/patient ratio: PD-L1+, atezo + bev, 25% and sunitinib, 35%; ITT, atezo + bev, 27% and sunitinib, 31%.

c P = 0.09. The OS analysis did not pass the P value boundary of α = 0.0009 at the first interim analysis.

Response and progression assessed by investigator; minimum follow-up, 12 months. Median follow-up, 15 months.

Motzer RJ, et al. ASCO GU 2018 [abstract 578].

(75)
(76)
(77)
(78)
(79)
(80)

Efficacy of therapy is improving…

Presented By Bradley McGregor at 2019 ASCO Annual Meeting

cc mRCC: I Line treatment

Conclusions

(81)

What we know now…

Presented By Bradley McGregor at 2019 ASCO Annual Meeting

cc mRCC: I Line treatment

Conclusions

(82)

1L Combination Therapy Trials of Approved Agents

Presented By Rana McKay at 2019 ASCO Annual Meeting

cc mRCC: I Line treatment

Conclusions

(83)

1L Combination Therapy Trials – ITT

Presented By Rana McKay at 2019 ASCO Annual Meeting

cc mRCC: I Line treatment

Conclusions

(84)
(85)

Slide 22

Presented By Neeraj Agarwal at 2019 ASCO Annual Meeting

(86)

Slide 23

Presented By Neeraj Agarwal at 2019 ASCO Annual Meeting

(87)

Sunitinib in mRCC with Brain Mets: Results from the Global Expanded Access Protocol

Presented By Neeraj Agarwal at 2019 ASCO Annual Meeting

(88)

Slide 25

Presented By Neeraj Agarwal at 2019 ASCO Annual Meeting

Riferimenti

Documenti correlati

Presented By Jeffrey Weber at 2018 ASCO Annual Meeting.. Subgroup Analysis of RFS: Disease Stage III and IV. Presented By Jeffrey Weber at 2018 ASCO Annual Meeting.. Keynote

I luoghi di questa riflessione sono molti, e la fatica che doveva fare Bianca Pitzorno nel suo bellissimo Storia delle mie storie (pubblicato per la prima volta nel 1995)

PANSS, positive and negative syndrome scale; PP, paliperidone palmitate; RIS, risperidone; RLAI, risperidone long-acting injection; SGAs, second-generation antipsychotics;

Presented By Martine Piccart-Gebhart at 2018 ASCO Annual Meeting.6. In favour of

Presented By Hedy Kindler at 2019 ASCO Annual Meeting... Come spiegare PFS

Presented By Claire Falandry at 2019 ASCO Annual Meeting... EWOC-1

Patients were not eligible for enrollment if any of the following applied: they had received a potentially effective antibiotic regimen for the current CR infection within 72 hrs

9 Eligible patients satis fied these inclusion criteria: cytological or histological diagnosis of epithelial ovarian cancer (including cancer of the fallopian tube and primary